|
|
 Previous Article | Table of Contents | Next Article 
Effect of PAI-1 levels on the molar concentrations of active tissue
plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma
WL Chandler, SL Trimble, SC Loo and D Mornin
Department of Laboratory Medicine, University of Washington, Seattle, WA
98195.
We determined the in vivo molar concentrations of active tissue plasminogen
activator (t-PA), active plasminogen activator inhibitor type 1 (PAI-1),
and t-PA/PAI-1 complex. t-PA activity was measured in plasma stabilized by
immediate acidification. PAI-1 activity and t- PA/PAI-1 complex antigen
were measured in citrated plasma; these measurements were corrected for the
loss in PAI-1 activity and increase in complex that occurs in unacidified
plasma samples due to the continued reaction between t-PA and PAI-1 after
the sample was drawn. To convert t-PA and PAI-1 activity measurements into
molar concentrations we determined the specific molar activity of t-PA and
PAI-1 in vivo: 4.48 x 10(13) IU/mol. Of 72 subjects studied, 13 had less
than 150 pmol/L active PAI-1; in these individuals 33% +/- 21% of their
t-PA was active and the molar ratio of active t-PA to active PAI- 1 was
0.20 +/- 0.13. In the 11 subjects with greater than 500 pmol/L active
PAI-1, 1.5% = 1.1% of the t-PA was active and the molar ratio of active
t-PA to active PAI-1 was 0.0043 +/- 0.0036. Overall, the fraction of active
t-PA declined exponentially as a function of the active PAI-1
concentration. During the day, the percentage of total t- PA that was
active increased from 12% at 8:00 AM to 31% at 8:00 PM, while the molar
ratio of active t-PA to active PAI-1 increased from 0.05 to 0.22 from
morning to evening (n = 12).
Volume 76,
Issue 5,
pp. 930-937,
09/01/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. J. Oliver, D. J. Webb, and D. E. Newby
Stimulated Tissue Plasminogen Activator Release as a Marker of Endothelial Function in Humans
Arterioscler. Thromb. Vasc. Biol.,
December 1, 2005;
25(12):
2470 - 2479.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
the Diabetes Prevention Program Research Group
Lipid, Lipoproteins, C-Reactive Protein, and Hemostatic Factors at Baseline in the Diabetes Prevention Program
Diabetes Care,
October 1, 2005;
28(10):
2472 - 2479.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. Horne III, K. K. Singh, K. G. Rosenfeld, R. Wesley, M. C. Skarulis, P. K. Merryman, A. Cullinane, R. Costello, A. Patterson, T. Eggerman, et al.
Is Thyroid Hormone Suppression Therapy Prothrombotic?
J. Clin. Endocrinol. Metab.,
September 1, 2004;
89(9):
4469 - 4473.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. E. Rabbani, N. A. Seminario, R. R. Sciacca, H. J. Chen, and E.-G. V. Giardina
Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women
J. Am. Coll. Cardiol.,
December 4, 2002;
40(11):
1991 - 1999.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Freeman, M. W. Mansfield, J. H. Barrett, and P. J. Grant
Genetic Contribution to Circulating Levels of Hemostatic Factors in Healthy Families With Effects of Known Genetic Polymorphisms on Heritability
Arterioscler. Thromb. Vasc. Biol.,
March 1, 2002;
22(3):
506 - 510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Watanabe, H. Wada, Y. Miura, Y. Murata, Y. Watanabe, M. Sakakura, Y. Okugawa, T. Nakasaki, Y. Mod, M. Nishikawa, et al.
Plasma Levels of Total Plasminogen Activator Inhibitor-I (PAI-I) and tPA/PAI-1 Complex in Patients With Disseminated Intravascular Coagulation and Thrombotic Thrombocytopenic Purpura
Clinical and Applied Thrombosis/Hemostasis,
July 1, 2001;
7(3):
229 - 233.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. Y. H. Lip and A. D. Blann
Does Hypertension Confer a Prothrombotic State? : Virchow’s Triad Revisited
Circulation,
January 25, 2000;
101(3):
218 - 220.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. L. Chandler, M. L. Jascur, and P. J. Henderson
Measurement of Different Forms of Tissue Plasminogen Activator in Plasma
Clin. Chem.,
January 1, 2000;
46(1):
38 - 46.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Dangas, J. J. Badimon, D. A. Smith, A. H. Unger, D. Levine, J. H. Shao, P. Meraj, C. Fier, J. T. Fallon, and J. A. Ambrose
Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile
J. Am. Coll. Cardiol.,
April 1, 1999;
33(5):
1294 - 1304.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. Macko, S. J. Kittner, A. Epstein, D. K. Cox, M. A. Wozniak, R. J. Wityk, B. J. Stern, M. A. Sloan, R. Sherwin, T. R. Price, et al.
Elevated Tissue Plasminogen Activator Antigen and Stroke Risk : The Stroke Prevention in Young Women Study
Stroke,
January 1, 1999;
30(1):
7 - 11.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. DeSouza, P. P. Jones, and D. R. Seals
Physical Activity Status and Adverse Age-Related Differences in Coagulation and Fibrinolytic Factors in Women
Arterioscler. Thromb. Vasc. Biol.,
March 1, 1998;
18(3):
362 - 368.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Margaglione, E. Grandone, G. Vecchione, G. Cappucci, N. Giuliani, D. Colaizzo, E. Celentano, S. Panico, and G. Di Minno
Plasminogen Activator Inhibitor-1 (PAI-1) Antigen Plasma Levels in Subjects Attending a Metabolic Ward: Relation to Polymorphisms of PAI-1 and Angiontensin Converting Enzyme (ACE) Genes
Arterioscler. Thromb. Vasc. Biol.,
October 1, 1997;
17(10):
2082 - 2087.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. L. Sacco, E. J. Benjamin, J. P. Broderick, M. Dyken, J. D. Easton, W. M. Feinberg, L. B. Goldstein, P. B. Gorelick, G. Howard, S. J. Kittner, et al.
Risk Factors
Stroke,
July 1, 1997;
28(7):
1507 - 1517.
[Full Text]
|
|
|
|
|
|
|
B. Fernhall, L. M. Szymanski, P. A. Gorman, J. Milani, D. C. Paup, and C. M. Kessler
Fibrinolytic Activity Is Similar in Physically Active Men With and Without a History of Myocardial Infarction
Arterioscler. Thromb. Vasc. Biol.,
June 1, 1997;
17(6):
1106 - 1113.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. F. Macko, S. F. Ameriso, A. Gruber, J. H. Griffin, J. A. Fernandez, R. Barndt, F. P. Quismorio, J. M. Weiner, and M. Fisher
Impairments of the Protein C System and Fibrinolysis in Infection-Associated Stroke
Stroke,
November 1, 1996;
27(11):
2005 - 2011.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
I. Juhan-Vague, S. D.M. Pyke, M. C. Alessi, J. Jespersen, F. Haverkate, and S. G. Thompson
Fibrinolytic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients With Angina Pectoris
Circulation,
November 1, 1996;
94(9):
2057 - 2063.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. A. DeSouza, D. R. Dengel, M. A. Rogers, K. Cox, and R. F. Macko
The Fibrinolytic System Is Not Impaired in Older Men With Hypertension
Hypertension,
May 1, 1996;
27(5):
1053 - 1058.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
W. L. Chandler, W. C. Levy, and J. R. Stratton
The Circulatory Regulation of TPA and UPA Secretion, Clearance, and Inhibition During Exercise and During the Infusion of Isoproterenol and Phenylephrine
Circulation,
November 15, 1995;
92(10):
2984 - 2994.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. G. Thompson, J. Kienast, S. D.M. Pyke, F. Haverkate, J. C.W. van de Loo, and The European Concerted Action on Thrombosis and Di
Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris
N. Engl. J. Med.,
March 9, 1995;
332(10):
635 - 641.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
